Hyperuricemia due to cancer therapy

Hyperuricemia due to cancer therapy is an acquired metabolic complication characterized by pathologically elevated serum uric acid concentrations triggered by antineoplastic treatments, such as cytotoxic chemotherapy, radiation, or targeted agents Commonly arising in pediatric and adult oncology patients undergoing treatment for high-burden or rapidly proliferating hematologic malignancies, it represents a defining hallmark of treatment-induced tumor lysis syndrome

Hyperuricemia due to cancer therapy is an acquired metabolic complication characterized by pathologically elevated serum uric acid concentrations triggered by antineoplastic treatments, such as cytotoxic chemotherapy, radiation, or targeted agents The underlying pathophysiology involves massive, therapy-induced cytolysis of malignant cells, which floods the systemic circulation with purine nucleic acids that are catabolized into uric acid This sudden surge overwhelms renal excretory capacity, pr...

Commonly arising in pediatric and adult oncology patients undergoing treatment for high-burden or rapidly proliferating hematologic malignancies, it represents a defining hallmark of treatment-induced tumor lysis syndrome

The underlying pathophysiology involves massive, therapy-induced cytolysis of malignant cells, which floods the systemic circulation with purine nucleic acids that are catabolized into uric acid This sudden surge overwhelms renal excretory capacity, predisposing the urinary system to tubular obstruction from uric acid crystal precipitation, acute urate nephropathy, and acute renal failure

This sudden surge overwhelms renal excretory capacity, predisposing the urinary system to tubular obstruction from uric acid crystal precipitation, acute urate nephropathy, and acute renal failure